Omeros (OMER) announced statistical analysis results related to the expanded access program for narsoplimab, Omeros’ ...
Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting the ...
5 天
Stocktwits on MSNSolid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's ...Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups. In fact, according ...
Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...
Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin ...
Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...
People with shorter telomeres, the protective caps at the end of chromosomes, inside their white blood cells may be more ...
He expressed his enthusiasm for joining Iovance at a pivotal time as the company catalyzes and expands the commercial launch ...
SAN CARLOS, Calif. - Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on novel cancer treatments, announced today the appointment of Dan Kirby (NYSE:KEX) as Chief ...
Taking place on February 14-16, 2025, in Washington, the American College of Cardiology (ACC) Advancing the Cardiovascular Care of the Oncology Patient conference is an interdisciplinary and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果